Clinical trials: Hepatic Neuroendocrine Carcinoma
Carcinoid Tumor
A Study of Axitinib in Advanced Carcinoid Tumors
The main purpose of this study is to see whether Axitinib will help prolong the time that the patient's carcinoid tumors remain stable, and to examine their treatment response through testing.
- Trial name
- NCT01435122
- Testing
- Axitinib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Neuroendocrine Tumor, Islet Cell Tumor
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
The purpose of this study is to decide if a medicine that slows growth of new blood vessels can be give after the embolization procedure to prevent or delay new growth of blood vessels to tumors.
- Trial name
- NCT00434109
- Testing
- Sunitinib malate, Hepatic Artery Embolizations
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Liver Neoplasms
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
This study is an open label prospective trial of TheraSphere treatment for patients who have liver metastases who have failed or are intolerant to other systemic or liver directed therapies.
- Trial name
- NCT01177007
- Testing
- TheraSphere, Yttrium-90 glass Microspheres
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx
Neuroendocrine Tumors, Brain (Nervous System) Cancers
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
A research study of liver perfusion (how blood flows to the liver over time). We hope to learn whether perfusion characteristics of liver masses may be predictive of response to treatment and whether liver perfusion…
- Conditions
- Neuroendocrine Tumors, Brain (Nervous System) Cancers, Colon/Rectal Cancer, Colon Cancer
- Trial name
- NCT01163526
- Testing
- CT perfusion
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stanford University
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Melanoma, Hodgkin Lymphoma
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors.
- Conditions
- Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)
- Trial name
- NCT06521567
- Testing
- Cobolimab, Dostarlimab
- Where
- 20 sites in United States, Czechia and 4 more
- Volunteers
- 83 people
- Sponsor
- GlaxoSmithKline
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Metastatic Cancer
- Trial name
- NCT00730483
- Testing
- PVA microporous hydrospheres/doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Yale University
Hepatocholangiocarcinoma, Fibrolamellar Carcinoma
A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy…
- Conditions
- Hepatocholangiocarcinoma, Fibrolamellar Carcinoma, Hepatic Epithelioid Hemangioendothelioma, Hepatoblastoma
- Trial name
- FFCD-2205 (NCT06541652)
- Where
- 40 sites in France
- Volunteers
- 150 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Head and Neck Cancer, Islet Cell Tumor
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Conditions
- Head and Neck Cancer, Islet Cell Tumor, Metastatic Cancer, Pheochromocytoma
- Trial name
- NCT00466856
- Testing
- octreotide acetate, yttrium Y 90 resin microspheres
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cancer Metastatic to the Liver, Hepatocellular Carcinoma
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
This open-label study will evaluate the safety, tolerability, pharmacokinetics and effect on tumor growth following a single intralesional injection of PV-10 in subjects with either (a) hepatocellular carcinoma (HCC) that is not…
- Conditions
- Cancer Metastatic to the Liver, Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Ocular Melanoma
- Trial name
- NCT00986661
- Testing
- PV-10 (10% rose bengal disodium)
- Where
- 5 sites in United States
- Volunteers
- 78 people
- Sponsor
- Provectus Biopharmaceuticals, Inc.
Liver Neoplasms
TheraSphere Japan Pre-Market Study
To investigate the safety and effectiveness of BSJ019T in Japanese patients with primary or secondary liver who are not candidate for standard treatment.
- Trial name
- INDIGO (NCT07377487)
- Testing
- TheraSphere Y-90 glass microsphere
- Where
- 5 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Boston Scientific Corporation
Breast Carcinoma, Carcinoma of Unknown Primary
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver…
- Conditions
- Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma
- Trial name
- NCT01366144
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 17 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Small Cell Lung Cancer (SCLC)
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
- Conditions
- Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin
- Trial name
- NCT07517198
- Testing
- EXS74539
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Ewing Sarcoma, Gastrointestinal Tumor
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
This is a phase I study designed to determine the feasibility of transplantation using a novel transplant approach that employs a two-stage haploidentical cell infusion following myeloablative conditioning.
- Conditions
- Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic Tumor
- Trial name
- NCT01625351
- Testing
- alemtuzumab, fludarabine, sirolimus
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- St. Jude Children's Research Hospital
Liver Cancer, Metastatic Cancer
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor.
- Trial name
- NCT00003907
- Testing
- cisplatin, doxorubicin, mitomycin
- Where
- 37 sites in United States
- Volunteers
- 50 people
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer, Colorectal Cancer
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00553683
- Testing
- cyclophosphamide, poly ICLC, hepatic artery embolization
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Colorectal Cancer, Islet Cell Tumor
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Conditions
- Colorectal Cancer, Islet Cell Tumor, Liver Cancer, Metastatic Cancer
- Trial name
- NCT00019786
- Testing
- isolated perfusion, melphalan, conventional surgery
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National Institutes of Health Clinical Center (CC)